Company profile
UK company 11333643, incorporated on 27 April 2018.
Refeyn - Measuring molecules with light
Our goal is to make mass photometry available to the scientific community. We specialise in label-free single molecule imaging and mass measurement of biomolecules in solution.
Company number 11333643
Updated 07 Jul 2026 09:49
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
AA | Transaction MzUzODc3NDU5M2FkaXF6a2N4 | Paper/PDF filed
Published 19 Aug 2026 22:54
Last confirmation statement made up date
Last accounts made up date
Company registered at Companies House
Refeyn develops technology that is capable of measuring and imaging molecular mass.
Refeyn Ltd is a spin-out from the University of Oxford, that employs ~30 people (most in Oxford, but also in the US and Germany) to develop mass photometry and make it available to the research community.
The company is new, but has attracted significant recent investment
Refeyn and sold and delivered instruments to labs around the world, with researchers in academia and industry using the instrumentation to perform new science. The company is revenue generating, and has raised significant amount of venture capital funding, and has created a diverse set of jobs.
1 Jun 2023 to 31 May 2025
The therapeutic potential for gene therapies is transformative, where many largely intractable diseases will be treated safely, effectively and durably. Therapies are now starting to get approved (e.g. Roctavian, Zolgensma, and Luxturna), but cost remains a large barrier to entry and widespread patient access, partly due to suboptimal manufacturing proces...
1 Oct 2020 to 30 Sep 2021
Gene therapy holds huge promise for many conditions that have been difficult to prevent or treat using conventional drugs, including inherited, rare and age-related diseases, and cancers. As the industry grows, there is an urgent need for more efficient, effective technologies for quality control tests. Technologies developed for traditional drugs have ma...
